Imagion Biosystems is pleased to announce a pro-rata renounceable rights issue (Offer) to fund the manufacture of the nanoparticle material, the undertaking of a first-in-human study (where sufficient capital is raised), and for general working capital purposes.
Read the Pro-Rata Renounceable Rights Issue.
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session